(Q51015158)

27 March 2018

title

A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a (English)

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(03)00225-9

30 March 2024

0 references

1 reference

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(03)00225-9

30 March 2024

1

Robert Zivadinov

1 reference

27 March 2018

Marino Zorzon

2

1 reference

27 March 2018

Maria Antonietta Tommasi

3

1 reference

27 March 2018

Davide Nasuelli

4

1 reference

27 March 2018

Monica Bernardi

5

1 reference

27 March 2018

Luisa Monti-Bragadin

6

1 reference

27 March 2018

Giuseppe Cazzato

7

1 reference

27 March 2018

language of work or name

English

1 reference

National Center for Biotechnology Information

PubMed ID

14607312

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14607312

30 March 2024

publication date

1 December 2003

1 reference

27 March 2018

15 December 2003

1 reference

National Center for Biotechnology Information

PubMed ID

14607312

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14607312

full work available at URL

30 March 2024

https://api.elsevier.com/content/article/PII:S0022510X03002259?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(03)00225-9

https://api.elsevier.com/content/article/PII:S0022510X03002259?httpAccept=text/plain

30 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(03)00225-9

Journal of the Neurological Sciences

30 March 2024

published in

1 reference

27 March 2018

volume

216

1 reference

27 March 2018

issue

1

1 reference

27 March 2018

page(s)

113-118

1 reference

27 March 2018

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900225-9

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900225-9

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900225-9

The quality-of-life effects of interferon beta-1b in multiple sclerosis. An extended Q-TWiST analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900225-9

Treatment with interferon beta-1b improves quality of life in multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900225-9

Interferon-beta1b in the treatment of secondary progressive MS: impact on quality of life.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900225-9

Quality of life in multiple sclerosis: influence of interferon-beta1 a (Avonex) treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900225-9

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900225-9

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900225-9

Defining the clinical course of multiple sclerosis: Results of an international survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900225-9

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900225-9

Validation of the functional assessment of multiple sclerosis quality of life instrument

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900225-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900225-9

Development of a Rating Scale for Primary Depressive Illness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900225-9

The assessment of anxiety states by rating

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900225-9

The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900225-9

Quality of life and its relationship to brain lesions and atrophy on magnetic resonance images in 60 patients with multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900225-9

Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900225-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900225-9

Multiple sclerosis: side effects of interferon beta therapy and their management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900225-9

7 January 2021

interferon beta-1a

13

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(03)00225-9

Side effect profile and adherence to in the treatment of multiple sclerosis with interferon beta-1a

30 March 2024

15

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(03)00225-9

30 March 2024

Identifiers

1 reference

27 March 2018

PubMed ID

14607312

1 reference

27 March 2018